Trial Profile
A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Mycoses; Nasal polyps; Rhinosinusitis
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 02 Feb 2024 Planned End Date changed from 21 Mar 2025 to 4 Mar 2025.
- 02 Feb 2024 Planned primary completion date changed from 27 Dec 2024 to 10 Dec 2024.
- 02 Feb 2024 Status changed from recruiting to active, no longer recruiting.